{"id":20802,"date":"2022-03-07T11:57:10","date_gmt":"2022-03-07T10:57:10","guid":{"rendered":"https:\/\/idibell.cat\/?p=20802"},"modified":"2022-03-07T11:57:32","modified_gmt":"2022-03-07T10:57:32","slug":"es-demostren-els-bons-resultats-de-la-robotica-en-la-cirurgia-de-cancer-de-coll-uteri","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2022\/03\/es-demostren-els-bons-resultats-de-la-robotica-en-la-cirurgia-de-cancer-de-coll-uteri\/","title":{"rendered":"Es demostren els bons resultats de la rob\u00f2tica en la cirurgia de c\u00e0ncer de coll uter\u00ed"},"content":{"rendered":"

La gran majoria de les infeccions pel virus del papil\u00b7loma hum\u00e0 no causen cap problema de salut, per\u00f2 en el cos de les dones que no poden combatre\u2019n la infecci\u00f3 viral, el VPH causa el c\u00e0ncer de c\u00e8rvix o de coll uter\u00ed. De fet, cada any se\u2019n diagnostiquen uns 2.000 casos a l\u2019Estat i a nivell mundial representa la quarta causa de mort per tumors malignes en dones.<\/p>\n

Una de les opcions per al tractament d\u2019aquest c\u00e0ncer ginecol\u00f2gic en fase inicial \u00e9s la histerectomia radical<\/strong>. Per tal de recollir evid\u00e8ncia, s\u2019han recollit les dades de 239 histerectomies radicals rob\u00f2tiques dutes a terme a la pen\u00ednsula entre 2009 i 2018 amb el sistema Da Vinci, en un \u00fanic registre nacional, que mant\u00e9 el grup de recerca ROBOCER. <\/strong><\/p>\n

El Dr. Jordi Ponce, responsable de la l\u00ednia d\u2019innovaci\u00f3 de cirurgia i rob\u00f2tica de l\u2019IDIBELL i cap del Servei de Ginecologia de l\u2019Hospital Universitari de Bellvitge (HUB), ha liderat aquest grup multic\u00e8ntric que ha comptat amb la participaci\u00f3 d\u2019equips dels hospitals terciaris de l\u2019Estat: Hospital Vall d\u2019Hebron, Hospital Universitari Virgen del Roc\u00edo (Sevilla), Hospital Cl\u00ednico San Carlos (Madrid) i Hospital Universitari de Basurto (Bilbao), entre d\u2019altres.<\/p>\n

 <\/p>\n

Evid\u00e8ncia a partir d\u2019una d\u00e8cada de registres<\/h3>\n

De l\u2019estudi de les dades registrades per ROBOCER, n\u2019han resultat dos articles publicats a la revista Cancers<\/em>.<\/p>\n

En el primer article<\/a>, de novembre de 2020, es determinen els factors de recurr\u00e8ncia del c\u00e0ncer de c\u00e8rvix <\/strong>despr\u00e9s de la cirurgia quir\u00fargica, que representen poc menys del 10% dels casos: tumors de grau 2 i 3, amb una mida superior a 20 mm, de tipus adenocarcinoma, entre altres trets en com\u00fa que tenen a veure amb proves diagn\u00f2stiques.<\/p>\n

Aquest febrer de 2022 s\u2019ha publicat el segon article<\/a> del grup a Cancers<\/em>, enfocat en identificar els factors que influeixen en els resultats oncol\u00f2gics segons la diferent pr\u00e0ctica cl\u00ednica entre centres hospitalaris.<\/p>\n

Com a conclusi\u00f3, els hospitals amb millors resultats oncol\u00f2gics s\u2019associen als que tenen un volum m\u00e9s alt de cirurgies rob\u00f2tiques<\/strong>, per\u00f2 tamb\u00e9 a un major nombre de proves preoperat\u00f2ries, bi\u00f2psies del gangli sentinella i major participaci\u00f3 en assajos cl\u00ednics. De fet, l\u2019HUB \u00e9s el centre hospitalari que m\u00e9s histerectomies amb robot duu a terme a l\u2019Estat i ha aportat un gran nombre de casos al registre nacional.<\/p>\n

En paral\u00b7lel, tamb\u00e9 s\u2019ha complert l\u2019objectiu d\u2019auditar els resultats oncol\u00f2gics i quir\u00fargics de les histerectomies radicals amb robot. Precisament, el grup ha pogut determinar que, en el nostre medi, l\u2019\u00fas de la cirurgia rob\u00f2tica permet superar els exigents objectius de qualitat <\/strong>proposats per la Societat Europea de Ginecologia Oncol\u00f2gica (ESGO)<\/a>.<\/p>\n

\u201cLa cirurgia rob\u00f2tica s\u2019ha consolidat com un est\u00e0ndard i una forma m\u00e9s acurada d\u2019operar, en comparaci\u00f3 a altres procediments com la laparosc\u00f2pia i, per descomptat, que la tradicional via oberta<\/em>\u201d, valora el Dr. Ponce<\/strong>, que afegeix: \u201cl\u2019estudi del registre nacional ROBOCER posa de manifest els bons resultats per al maneig del c\u00e0ncer de coll uter\u00ed. Ara esperem aviat poder extreure conclusions del registre ROBOEND de dades sobre les cirurgies rob\u00f2tiques dels darrers cinc anys per al tractament del c\u00e0ncer d\u2019endometri a Espanya i Portugal<\/em>\u201d.<\/p>\n

La recent incorporaci\u00f3 d\u2019un tercer robot Da Vinci al bloc quir\u00fargic de l\u2019HUB far\u00e0 possible l\u2019increment encara major de l\u2019activitat rob\u00f2tica en Ginecologia al nostre centre.<\/p>\n

A m\u00e9s, el Servei de Ginecologia de l\u2019Hospital Universitari de Bellvitge ha estat reacreditat per l\u2019ESGO<\/a> com a centre d\u2019excel\u00b7l\u00e8ncia, formador de la subespecialitat europea de Ginecologia Oncol\u00f2gica en un rigor\u00f3s programa de fellows <\/em>amb t\u00edtol reconegut arreu d\u2019Europa.<\/p>\n

 <\/p>\n

 <\/p>\n

L\u2019Institut d’Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) \u00e9s un centre de recerca en biomedicina creat l\u2019any 2004. Est\u00e0 participat per l’Hospital Universitari de Bellvitge i l\u2019Hospital de Viladecans de l’Institut Catal\u00e0 de la Salut, l’Institut Catal\u00e0 d’Oncologia, la Universitat de Barcelona i l\u2019Ajuntament de l\u2019Hospitalet de Llobregat.<\/em><\/p>\n

L\u2019IDIBELL \u00e9s membre del Campus d’Excel\u00b7l\u00e8ncia Internacional de la Universitat de Barcelona HUBc i forma part de la instituci\u00f3 CERCA de la Generalitat de Catalunya. L’any 2009 es va convertir en un dels cinc primers centres d\u2019investigaci\u00f3 espanyols acreditats com a institut d\u2019investigaci\u00f3 sanit\u00e0ria per l\u2019Instituto de Salud Carlos III. A m\u00e9s, forma part del programa \u201cHR Excellence in Research\u201d de la Uni\u00f3 Europea i \u00e9s membre de EATRIS i REGIC. Des de l\u2019any 2018, l\u2019IDIBELL \u00e9s un Centro Acreditado de la Fundaci\u00f3n Cient\u00edfica AECC (FCAECC).<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

El registre nacional ROBOCER, liderat per l\u2019IDIBELL i l\u2019Hospital Universitari de Bellvitge, ha contribu\u00eft a extreure els avantatges de la cirurgia rob\u00f2tica a partir de les dades de tots els casos de c\u00e0ncer de c\u00e8rvix operats amb el robot Da Vinci a l\u2019Estat des de 2009. Les conclusions del darrer estudi s\u2019han recollit en un article cient\u00edfic publicat aquest febrer a la revista Cancers.<\/p>\n","protected":false},"author":8,"featured_media":20803,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[332,365,447],"tags":[],"class_list":["post-20802","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancer","category-cancer-ginecologic","category-p-de-mecanismes-molelculars-i-terapia-experimental-en-oncologia-oncobell"],"publishpress_future_action":{"enabled":false,"date":"2024-11-29 03:57:59","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/20802","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=20802"}],"version-history":[{"count":1,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/20802\/revisions"}],"predecessor-version":[{"id":20804,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/20802\/revisions\/20804"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/20803"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=20802"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=20802"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=20802"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}